at the end of the three-year sales period, the largest shareholder and the sixth largest shareholder of Pharmaron Beijing Co.Ltd(300759) (300759), a leader in innovative drug research and development, have launched a reduction plan.
On January 25, Pharmaron Beijing Co.Ltd(300759) announced that the shareholders Xinzhong Kangcheng and Xinzhong Longcheng planned to reduce their holdings by no more than 6% in total. The reason for the reduction was their own capital needs. If estimated at the latest closing price of 130.49 yuan, the maximum reduction amount of the two shareholders was about 6 billion yuan.
From the secondary market, the stock price of Pharmaron Beijing Co.Ltd(300759) has continued to decline in recent five months, with a cumulative decline of more than 40%. However, despite the obvious correction of the company’s share price, the issue price of Pharmaron Beijing Co.Ltd(300759) is only 7.66 yuan / share, and the holding cost of the original shareholders is much lower than the issue price, which means that the shareholders who lift the ban will gain a lot.
It is worth noting that Pharmaron Beijing Co.Ltd(300759) is also the fifth largest heavy position stock of China Europe medical health, the representative work of Ge Lan, the new top flow fund manager of 100 billion. At the same time, it is also the public fund with the largest position of Pharmaron Beijing Co.Ltd(300759) .
total reduction of two shareholders 6%
On January 25, Pharmaron Beijing Co.Ltd(300759) threw out a pre disclosure announcement of the reduction plan of major shareholders.
According to the announcement, the shareholder Xinzhong Kangcheng, who holds 157 million shares of Pharmaron Beijing Co.Ltd(300759) shares (accounting for 19.79% of the total share capital), plans to reduce the company’s shares by no more than 31.767 million shares (accounting for 4% of the total share capital) in legal ways recognized by Shenzhen Stock exchange, such as block trading, centralized bidding trading and agreement transfer.
Meanwhile, the shareholder Xinzhong Longcheng, who holds 28.494 million Pharmaron Beijing Co.Ltd(300759) shares (accounting for 3.59% of the total share capital), plans to reduce the company’s shares by no more than 15.8835 million shares (accounting for 2% of the total share capital) in legal ways recognized by Shenzhen Stock Exchange, such as block trading, centralized bidding trading and agreement transfer.
This means that the two shareholders plan to reduce Pharmaron Beijing Co.Ltd(300759) shares by no more than 6%. According to the third quarterly report of last year, xinzhongkang became the largest shareholder of the company and xinzhonglong became the sixth largest shareholder of the company.
From the secondary market, after hitting the history of 244 yuan per share in August last year, Pharmaron Beijing Co.Ltd(300759) share price continued to adjust, and has fallen by more than 40% so far. The latest closing price is 130.49 yuan per share. If estimated at this price, the maximum reduction amount of the two shareholders is about 6 billion yuan.
Although the stock price of Pharmaron Beijing Co.Ltd(300759) has been significantly corrected recently, the issue price of the company is only 7.66 yuan / share. In addition, the holding cost of the original shareholders is much lower than the issue price, which means that the lifting of the ban has a lot of benefits for shareholders.
It is worth noting that Pharmaron Beijing Co.Ltd(300759) is one of the largest companies to lift the ban this week. Data show that a total of 72 companies lifted the ban on restricted shares this week, with a total of 7.372 billion shares, with a market value of about 190 billion yuan. The market value of Pharmaron Beijing Co.Ltd(300759) lifted exceeded 40 billion yuan.
According to the previous announcement, Pharmaron Beijing Co.Ltd(300759) will usher in the lifting of the ban on the first restricted shares listed for three years on January 28, with a new circulation of 373 million shares, accounting for 46.97% of the total share capital, which is 1.31 times that of the circulation before the lifting of the ban.
The lifting of the ban involves 11 shareholders, including Shenzhen xinzhongkangcheng investment partnership, pharmaron Holdings Limited, Shenzhen xinzhonglongcheng investment partnership, Ningbo longtaikang Investment Management Co., Ltd., Beijing Duotai Investment Management Co., Ltd. and Lou Xiaoqiang, the actual controller of the company, which is also a major background for the reduction of the two major shareholders.
Pharmaron Beijing Co.Ltd(300759) is the second largest pharmaceutical R & D service platform (CRO) in China. Not long ago, the company also issued a performance forecast announcement for 2021.
On January 21, Pharmaron Beijing Co.Ltd(300759) announced that it is expected to achieve an operating revenue of 7.341 billion yuan – 7.495 billion yuan in 2021, with a year-on-year increase of 43% – 46%; The net profit attributable to the parent company was 1.583-1.7 billion yuan, with a year-on-year increase of 35% – 45%; Deduct non net profit of RMB 1.281 billion to RMB 1.361 billion, with a year-on-year increase of 60% – 70%.
Referring to the performance, Pharmaron Beijing Co.Ltd(300759) said that the company’s business plan was carried out in an orderly manner. In 2021, the main business income increased steadily, the economies of scale, operation efficiency and profitability of mature service lines were gradually improved; The company continues to promote the layout and development of new business, and the gross profit margin of new business is relatively low in the investment stage; The company’s revenue is mainly denominated in US dollars. The average exchange rate of US dollars to RMB in 2021 decreased significantly by about 6.5% compared with the previous year, which has a certain negative impact on the company’s operating revenue and net profit
one of Ge Lan’s heavy positions
It is worth noting that Pharmaron Beijing Co.Ltd(300759) is also one of the heavyweight stocks of China Europe medical and health, the representative work of Ge Lan, the new top flow fund manager of 100 billion.
On January 22, five funds managed by Ge Lan released the fourth quarter report of 2021. By the end of 2021, the management scale of Ge Lan had exceeded 100 billion yuan, reaching 110.339 billion yuan. In terms of positions, the China EU medical and health quarterly managed by Glenn showed that the stock position of the fund was 81.47% by the end of the fourth quarter of 2021, down 8.15 percentage points from the third quarter.
In the four seasons report, Glenn said that the overall operation of high positions was maintained in the fourth quarter of 2021, focusing on the long-term promising innovative drug industry chain, medical services and leading enterprises of high-quality generic drugs. At the end of the fourth quarter of 2021, the top ten heavyweight stocks of China EU healthcare were: Wuxi Apptec Co.Ltd(603259) , Aier Eye Hospital Group Co.Ltd(300015) , Asymchem Laboratories (Tianjin) Co.Ltd(002821) , Hangzhou Tigermed Consulting Co.Ltd(300347) , Pharmaron Beijing Co.Ltd(300759) , Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) , Zhangzhou Pientzehuang Pharmaceutical Co.Ltd(600436) , Topchoice Medical Co.Inc(600763) , Porton Pharma Solutions Ltd(300363) , Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) .
It is worth noting that gran is still optimistic about the direction of the innovative drug industry chain. “From the perspective of future allocation, the innovative drug industry chain is still the most promising direction for a long time. From the top-level design of policies to the innovation accumulation of Chinese enterprises in recent years, China’s innovative drug industry chain has been maintained in a state of high vision for a long time. In addition, with the improvement of Chinese residents’ consumption ability, knowledge structure and cognitive level, the penetration rate of products and services and Residents’ ability to pay has been continuously improved, and leading enterprises in relevant industries also have long-term growth space. ” Glenn said.
However, with the recent continuous decline of pharmaceutical stocks, China EU medical and health industry is also regarded as constantly “stepping on thunder” in investment.
